France: Treatment of pharmaceutical company’s rebates for VAT purposes; refund opportunities
France: Treatment of pharmaceutical company’s rebates
France’s Supreme Tax Court (“Conseil d’Etat”) held that for value added tax (VAT) purposes, companies can reduce their taxable base to reflect certain “conventional rebates.”
The case is: Janssen Cilag (12 March 2021).
The rebates were paid under agreements of the “economic comity for health products” (comité économique des produits de santé) regime. The position of the tax authorities was that such rebates were “financial penalties” that could not be used to reduce the taxable base for VAT purposes.
The Conseil d’Etat agreed with prior findings of the Administrative Court of Appeal, Versailles, that conventional discounts paid by pharmaceutical companies could be subtracted or deducted, for VAT purposes, from the taxable base regarding sales previously made by the companies and for which the discounts were due.
All levels of French courts have applied a judgment of the Court of Justice of the European Union (CJEU)—the Boehringer Ingelheim Pharma case (C-462/16, 20 December 2017)—to determine the VAT treatment of rebates.
Now that the Conseil d’Etat has issued its decision on the VAT treatment of certain rebates, eligible pharmaceutical companies can reduce their taxable base by the amount of discounts paid.
Going forward, it will be prudent to classify the types of discounts or rebates. Also, there could be VAT refund opportunities for rebates made during the years 2019, 2020, and 2021.
Read a March 2021 report [PDF 65 KB] prepared by the KPMG member firm in France
For more information, contact a tax professional with KPMG Avocat:
Laurent Chetcuti | +33 1 55 68 48 87 | firstname.lastname@example.org
The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization. KPMG International Limited is a private English company limited by guarantee and does not provide services to clients. No member firm has any authority to obligate or bind KPMG International or any other member firm vis-à-vis third parties, nor does KPMG International have any such authority to obligate or bind any member firm. The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act on such information without appropriate professional advice after a thorough examination of the particular situation. For more information, contact KPMG's Federal Tax Legislative and Regulatory Services Group at: + 1 202 533 4366, 1801 K Street NW, Washington, DC 20006.